Tectonic Therapeutic, Inc.
NASDAQ•TECX
CEO: Dr. Alise S. Reicin M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date:
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Contact Information
Market Cap
$571.36M
P/E (TTM)
-6.8
24.5
Dividend Yield
--
52W High
$36.03
52W Low
$14.39
52W Range
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 9-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2025
Financial Dashboard
Q1 2026 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$1.34+0.00%
4-Quarter Trend
FCF
-$18.43M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
TX45 Phase 1b Hemodynamics Positive TX45 showed 19.0% PCWP reduction in PH-HFpEF patients; HFrEF cohort saw 29.2% PCWP reduction.
R&D Spending Rises 53% Research and development expenses reached $63.5M USD, increasing 53% driven by TX45 and TX2100 advancement.
Strong 2025 Financing Activity Financing activities provided $173.4M USD, mainly from the February 2025 Private Placement to fund operations.
Cash Position Strong Cash and equivalents totaled $253.8M USD as of December 31, 2025, sufficient for over 12 months operations.
Risk Factors
Net Loss Increased 28% Net loss widened to $74.2M USD in 2025, reflecting ongoing high research and development investment costs.
Platform Development Uncertainty GEODe™ platform is early stage; clinical trials are lengthy, expensive, and success in regulatory approval is not guaranteed.
Reliance on Single Manufacturer Sole-source relationship with WuXi Biologics for TX45 supply poses risk from potential supply chain disruptions or regulatory issues.
Substantial Future Capital Needed Substantial additional funding required to complete Phase 3 trials and commercialization; failure to raise capital may halt development.
Outlook
TX45 APEX Trial Data Expected Expect topline results from ongoing TX45 APEX Phase 2 clinical trial in PH-HFpEF patients during 2026.
TX2100 Phase 1a Results Due Anticipate topline results from the TX2100 Phase 1a healthy volunteer clinical trial in the fourth quarter of 2026.
TX45 PH-ILD Phase 2 Planned Plan to initiate a Phase 2 clinical trial for TX45 in Group 3 PH-ILD patients, an orphan disease indication.
GEODe™ Platform Enhancements Continue enhancing GEODe™ platform, focusing on improved GPCR engineering, yeast display protocols, and biophysical properties.
Peer Comparison
Revenue (TTM)
$217.78M
$214.88M
$68.09M
Gross Margin (Latest Quarter)
100.0%
90.0%
80.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CAPR | $1.18B | -12.9 | -59.3% | 6.5% |
| DRTS | $889.71M | -15.5 | -73.2% | 13.2% |
| TECX | $571.36M | -6.8 | -32.3% | 1.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data